C.E.M. Griffiths - Concepedia

Author

C.E.M. Griffiths

Also Known As

A David Burden, Anea Evans, Arents, Bernd, B.J Nickoloff, Bhushan, C E Griffiths, C E M GRIFFITHS, C E M Griffiths, C EM Griffiths, C GRIFFITHS

1.3K

Publications

71.9K

Citations

132

H-Index

296

Concepts

All Affiliations

University of Manchester Manchester Academic Health Science Centre Salford Royal Hospital Salford Royal NHS Foundation Trust NIHR Manchester Biomedical Research Centre

About

C.E.M. Griffiths is an author at University of Manchester specializing in medicine, dermatology, and psoriatic arthritis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	74	187	18.4K
2	Engineering	10	10	771
3	Health Sciences	6	6	375
4	Natural Sciences	4	4	92
5	Education	3	3	332

C.E.M. Griffiths

502

Publications

47.3K

Citations

114

H-Index

Page 1

	Year	Citations
Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials Richard G. Langley, Boni E. Elewski, Mark Lebwohl, New England Journal of Medicine	2014	1.9K
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham, The Lancet AllergyAtopic DermatitisAllergy MedicineModerate-to-severe Atopic DermatitisSkin Allergy	2017	1.2K
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial Kristian Reich, Frank O. Nestlé, Kim Papp, The Lancet Infliximab InductionSystemic TreatmentPhase IiiClinical TrialsPsoriatic Arthritis	2005	1K
Definition of treatment goals for moderate to severe psoriasis: a European consensus Ulrich Mrowietz, Knud Kragballe, Kristian Reich, Archives of Dermatological Research	2010	868
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis C.E.M. Griffiths, Bruce Strober, Peter van de Kerkhof, New England Journal of Medicine	2010	845
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial Andrew Blauvelt, Kim Papp, C.E.M. Griffiths, Journal of the American Academy of Dermatology	2017	838
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials C.E.M. Griffiths, Kristian Reich, Mark Lebwohl, The Lancet Randomised TrialsClinical TrialsClinical DermatologyDermatologyExperimental Dermatology	2015	815
European S3‐Guidelines on the systemic treatment of psoriasis vulgaris Delano Pathirana, AD Ormerod, P. Saïag, Journal of the European Academy of Dermatology and Venereology	2009	695
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction Kim Papp, Stephen K. Tyring, M. Lahfa, British Journal of Dermatology	2005	687
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1) Kim Papp, Kristian Reich, Craig L. Leonardi, Journal of the American Academy of Dermatology Autoimmune DiseaseMedicinePhase IiiClinical TrialsPlaque Psoriasis	2015	649

Page 1